Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM SR versus DYNACIRC CR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM SR versus DYNACIRC CR.
CARDIZEM SR vs DYNACIRC CR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes during depolarization, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Oral: Initial dose 60-120 mg twice daily; titrate to maximum 360 mg/day divided into two doses.
Isradipine extended-release (DynaCirc CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
None Documented
None Documented
3.0-4.5 hours for diltiazem; metabolites (e.g., desacetyldiltiazem) up to 10 hours. Clinical context: dosing interval adjustment in hepatic impairment.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Renal: 2-4% unchanged; hepatic metabolism: ~60-70% (including active metabolites); fecal: ~30-40%.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker